Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years

Learn more about:
Related Clinical Trial
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types Early Detection of Vulval CAncer Through Self-Examination (EDuCATE): Intervention Study Education, Immigration and HPV Vaccination: an Informational Randomized Trial Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years Serial MRI Scans During Radiation Therapy A Safety and Efficacy Study of Intra-tumoural Diffusing Alpha Radiation Emitters for the Treatment of Vulva Cancer Indocyanine Green Fluorescence Imaging, Sentinel Lymph Node Mapping in Patients With Vulvar Cancer Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females Cisplatin+Pembrolizumab+RT in Vulvar Cancer Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations Developing a Stepped Approach to Improving Sexual Function aFteR Treatment fOr gyNaecological Cancer Integrating a Health Information Technology System for Primary and Secondary Cervical Cancer Prevention Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer Prospective Evaluation of Lymphoedema Among Patients With Gynaecological Cancer Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery MR-HIFU for Recurrent Gynaecological Cancer Pelvic Floor Disorders in Survivors of Gynecologic Malignancies Outcomes From Home in Patients Recovering From Major Gynecologic Cancer Surgery: Measuring Symptoms and Health-related Quality of Life Paclitaxel Therapeutic Drug Monitoring in Cancer Patients Validation of a Nutrition Screening Tool A Survivorship Care Plan for Gynaecological Cancer Patients Self-Advocacy Serious Game in Advanced Cancer Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED) Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001) Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002) Chemoradiation-Induced Nausea and Emesis: Quality of Life A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021) A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002) Longitudinal Evaluation of Women Undergoing Pelvic Exenteration for Treatment of Gynecologic Malignancy Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies ChemoFx® PRO – A Post-Market Data Collection Study Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females Colposcopy and High Resolution Anoscopy in Screening For Anal Dysplasia in Patients With Cervical, Vaginal, or Vulvar Dysplasia or Cancer Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life The Lifestyle and Empowerment Techniques in Survivorship of Gynecologic Oncology Study Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer Image-Guided Gynecologic Brachytherapy Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial Cancer Topical Imiquimod in Treating Patients With Recurrent Paget’s Disease of the Vulva Antineoplaston Therapy in Treating Patients With Stage IV Cancer of the Cervix and/or Vulva Chemoprevention of Cancer in the Lower Female Genital Tract: The Antineoplastic Activity of the Fungicide Ciclopirox. The Impact of the “WOMAN-PRO II Program” on Patients With Vulvar Neoplasia to Minimize Post-surgical Symptom Prevalence CaptHPV : Validation of the Method “CaptHPV” for the Diagnosis of Human Papillomavirus Associated Infiltrating Carcinomas Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers Effectiveness of an Individualized Symptom Education Program (ISEP) A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) Paclitaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Vulva A Non-Randomized Study to Evaluate Leg Lymphatic Drainage Associated With Surgical Intervention for Vulvar Cancer Radiation Therapy or Surgery in Treating Patients With Previously Untreated Vulva Cancer With Positive Groin Lymph Nodes Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection Study to Evaluate the Role of PlasmaJet in Patients Undergoing Groin Node Dissection for Vulval Cancer Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva Added-value of SPECT/CT in Patients Undergoing LM/SL for Gynecological Cancers Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer OCT-AF Imaging of Pre-cancers of Vulva and Cervix Fibrin Sealant in Decreasing Lymphedema Following Surgery to Remove Lymph Nodes in Patients With Cancer of the Vulva Groin Sentinel Node Biopsy and 18FDG-PET/CT in cN0 Vulvar Cancer Patients Candidate to Standard Lymphadenectomy Ultrasound Morphometric and Cyto/Histological Combined Pre-operative Assessment of Inguinal Lymph Node Status in Women With Invasive Vulvar Carcinoma Lymphatic Mapping in Treating Patients With Stage I or Stage II Cancer of the Vulva Conservative Management With Isolated Sentinel Lymph Node Biopsy in Vulvar Cancer Patients. Quality of Life, Unmet Needs and Satisfaction With Care After Vulvar Cancer Sentinel Node Extended in Squamous Cell Vulvar Cancer Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer. Radiation Therapy With or Without Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Cancer of the Vulva

Brief Title

Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years

Official Title

Evaluating the Immunogenicity and Safety of 9-valent Human Papillomavirus(Type6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine in Chinese Females Aged 9 to 45 Years: A Phase 3, Open-label, Non-randomised Clinical Trial

Brief Summary

      This phase 3 study will evaluate the immunogenicity and safety of 9-valent HPV recombinant
      vaccine in Chinese females aged 9 to 45 years

Detailed Description

      This study (protocol 9-HPV-3003) is an immunogenicity and safety study in the subjects (9-19
      years of age) who received the 9-valent HPV recombinant vaccine compared with the subjects
      (20-45 years of age). In this study, we will assess whether the immunogenicity of the
      9-valent HPV vaccine given 3-dose schedule in the subjects (9-19 years of age) in noninferior
      to that in the subjects (20-45 years of age) receiving 3 doses, while assessing the safety of
      this vaccine.

Study Phase

Phase 3

Study Type


Primary Outcome

The primary immunogenicity objective

Secondary Outcome

 Number of patients with postive antibodies after the whole schedule vaccination from the former negative subjects


HPV Infections


9-valent HPV vaccine

Study Arms / Comparison Groups

 9-valent HPV vaccine
Description:  9-valent HPV recombinant vaccine (Hansenula Polymorpha) All subjects aged 9 to 45 years received 3 doses of 9v HPV vaccine at 0,2,6 month scehdule


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

May 28, 2021

Completion Date

May 2026

Primary Completion Date

December 2021

Eligibility Criteria

        Inclusion Criteria:

        Inclusion Criteria for the first stage:

          1. Healthy Chinese females aged 9 to 45 years; Provide legal identification;

          2. The subject voluntarily agrees to enroll in this study. If the subject is a minor,
             both the subject and subject's legal guardian should voluntarily agree to enroll in
             this study and sign an informed consent form;

          3. Be able to understand the study procedures and promise to participate in regular
             follow-ups under the requirements;

          4. Had a negative urine pregnancy test on the day of enrollment, among the subjects of
             childbearing age; Not in the duration of breast-feeding and no birth plan within 7
             months; According to the investigator's judgment that there is no possibility of
             pregnancy at that time: subjects have taken effective contraception, or asexual life
             after the last menstrual period, or use IUD, or had undergone ligation; subjects agree
             to continue take effective contraception such as taking OCS and condom use;

          5. No fever symptoms on the day of enrollment (aged> 14 years old, axillary
             temperature<37.3°C; aged ≤ 14 years old, axillary temperature<37.5°C );

             Inclusion Criteria for the second stage:

          6. Received all 3 doses of trial vaccination;

          7. Subjects aged 9 to 19 years at the first stage.

        Exclusion Criteria:

          1. Received marketed HPV vaccine or plan to receive marketed HPV vaccine during this
             study period or have enrolled in HPV vaccine clinical trials;

          2. History of positive test to HPV, history of cervical cancer (e.g. abnormal screening
             test results, abnormal cervical biopsy results, including CIN, AIS, and cervical
             cancer) or history of hysterectomy (vaginal or abdominal radical hysterectomy), or
             history of pelvic radiotherapy; History of genital diseases related to HPV infection
             (e.g. uterine peristalsis, VIN, VAIN, AIN, and related cancers); History of STDs,
             including syphilis, gonorrhea, genital herpes, Mycoplasma genitalium, Lymphgranuloma
             Venereum, granuloma inguinale, etc.;

          3. Known allergy to any vaccine components or history of severe allergic diseases
             requiring treatment, including shock, laryngeal edema, urticarial, Henoch-Schonlein
             purpura, Arthus reaction, etc.;

          4. Had primary or acquired immunodeficiency such as HIV, SLE, JRA, etc. or received
             immunosuppressive treatment within one month before study such as long-term
             glucocorticoid use(≥2mg per kg per day, lasted more than two wks), or plan to receive
             such treatment from day 0 to month 7 after the last dose;

          5. Had chronic diseases or congenital malformations, which might interfere with the
             process and completion of this study, such as Down Syndrome, heart diseases, liver
             diseases, chronic diabetes complications, and malignant tumor;

          6. Enrolling or plan to enroll in other clinical trials (drug or vaccine);

          7. Had infectious diseases such as TB, viral hepatitis, and/or HIV infection;

          8. Had convulsions, epilepsy, encephalopathy, and mental illness or family history;

          9. With prohibitive contraindications such as Thrombocytopenia or coagulopathy;

         10. Asplenic, functionally asplenic, or splenectomy caused by any condition;

         11. Within 3 days prior to vaccination, have an acute disease or are in the acute attack
             of a chronic disease or have used antipyretic, analgesic and anti-allergic drugs (such
             as: acetaminophen, ibuprofen, aspirin, loratadine, ceti Rizine, etc.);

         12. Receipt of inactivated or recombinant vaccines within 14 days, live vaccines within 28

         13. Receipt of immune globulin or blood-related products within 3 months; or plan to
             receive such products during this study period;

         14. Had fever symptoms within 24 hours on the first day (aged> 14 years old, axillary
             temperature ≥ 37.3°C; aged ≤ 14 years old, axillary temperature ≥37.5°C );

         15. Untreated/uncontrolled hypertension before vaccination (aged 9 to 17 years: systolic
             BP>120mmHg and/or diastolic BP>80mmHg; aged more than 18 years: Systolic BP≥140mmHg
             and/or diastolic BP ≥90mmHg);

         16. Plan to permanently relocate from the area before the end of the study or leave the
             local area for a long time during the study visit (affecting the scheduled visit

         17. According to the investigator's judgment, the subject has any condition may interfere
             with process of evaluation or participating in this study cannot guarantee the
             object's maximum benefit.




9 Years - 45 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers


Person(s) responsible for the overall scientific leadership of Lv, 13588458021, [email protected]

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party


Study Sponsor

Shanghai Bovax Biotechnology Co., Ltd.


 Chongqing Bovax Biopharmaceutical Co., Ltd.

Study Sponsor

Person(s) responsible for the overall scientific leadership of Lv, Study Director, Zhejiang Provincial Center for Disease Control and Prevention

Verification Date

May 2021